Hematopoietic Stem Cell Transplantation after Posttransplant Lymphoproliferative Disorder

A 16-yr-old girl received liver transplantation for fulminant hepatitis. Aplastic anemia developed, and she received hematopoietic stem cell transplantation (HSCT). Eleven months after liver transplantation, abdominal lymph node enlargement and colon ulcers were observed, and colon biopsy showed posttransplant lymphoproliferative disorder (PTLD). Immunosuppression reduction was attempted, but it produced no therapeutic effect. Fourteen months after liver transplantation, she received a second HSCT due to engraftment failure, and PTLD resolved completely. The second HSCT can serve as cellular therapy for PTLD.

Key Words: Posttransplant Lymphoproliferative Disorder, Hematopoietic Stem Cell Transplantation; Liver Transplantation

INTRODUCTION

Posttransplant lymphoproliferative disorder (PTLD) is one of the most serious complications after solid organ transplantation and hematopoietic stem cell transplantation (HSCT). The incidence has been reported to be about 1 percent of all transplantations (1, 2). PTLDs, including polyclonal lymphoproliferation of B lymphocytes, polymorphic PTLD and monomorphic B-cell lymphoma, are extremely heterogeneous.

The risk factors for PTLD include the Epstein-Barr virus (EBV) serostatus, primary EBV infection, type of organ transplant, intensity of immunosuppression, presence of cytomegalovirus disease, and age (3-6). EBV infection is thought to play the most important role in the pathogenesis of PTLD (7). During primary EBV infection, EBV infects, transforms and immortalizes host B lymphocytes, and the individual becomes a permanent carrier. EBV-infected B lymphocytes commonly remain in the latent state, protected from viral proteins by preventing death by apoptosis and from causing proliferation. In immunocompetent hosts, the proliferation of B lymphocytes is inhibited by cytotoxic T cells. However, in organ transplant recipients, T-cell function is inhibited through the use of immunosuppressants. Therefore, EBV induces uncontrolled B-cell expansion, resulting in PTLD. In other words, deficiencies of EBV-specific T-cell-mediated immunity may cause PTLD (7-12).

PTLD is successfully treated by reducing immunosuppression. Other treatment methods such as chemotherapy, radiation therapy, antiviral therapy, anti-B-cell monoclonal antibody, and cytotoxic T cells are currently being investigated.

CASE REPORT

A 16-yr-old Korean girl who was previously healthy developed jaundice in March 2005. It progressed to acute fulminant hepatitis 1 month later. A diagnosis of Wilson disease was made on the basis of increased copper in 24-hr urine and a Kayser-Fleischer ring on cornea examination. In April 2005, she received cadaveric liver transplantation. Before transplantation, IgG antibody against viral capsid antigen (VCA) and IgG antibody against Epstein-Barr nuclear antigen (EBNA) were positive, and early antigen (EA) was negative. After liver transplantation, IgG antibody against EA converted to being positive.

Before liver transplantation, there was no cytopenia in blood tests. However, pancytopenia developed after liver transplantation. Absolute neutrophil counts were below 200/μL, which was compatible with severe aplastic anemia. In September 2005, immunotherapy with antilymphocyte globulin (ALG), methylprednisolone and cyclosporine was performed to treat aplastic anemia, but it produced little therapeutic effect.
In January 2006, she received a bone marrow transplant from an unrelated 39-yr-old Korean man who had 4 HLA Ag mismatch (CD34: 1.69 × 10⁶/kg). The conditioning regimen consisted of fludarabine, antithymocyte globulin (ATG) and cyclophosphamide. ATG depleted T lymphocytes. After transplantation, immunosuppressive induction was performed with cyclosporine but engraftment was failed.

Eleven months after liver transplantation, hematochezia developed. We performed computed tomography (CT) of the abdomen and colonoscopy in order to find the cause of hematochezia. Abdomen CT revealed lymph node enlargement in the mesentery and paraaortic area (Fig. 1). Multiple aphthoid ulcers were found during colonoscopy (Fig. 2). Colon biopsy showed monoclonal B-cell proliferation, which was compatible with polymorphic PTLD (Fig. 3). Positive results for EBV in situ hybridization (Fig. 4) and immunoglobulin heavy chain gene rearrangement were obtained. In addition, EBV DNA was detected by the polymerase chain reaction.

Fig. 1. Abdomen CT 11 months after liver transplantation. Multiple conglomerated lymphadenopathies in the mesentery and para-aortic areas (arrow) were newly appeared.

Fig. 2. Sigmoidoscopy on day 55 after the first HSCT. Multiple aphthoid ulcers (arrow) were shown.

Fig. 3. Colon biopsy. H&E stain, original magnification.

Fig. 4. Colon biopsy. EBV in situ hybridization of the colon biopsy specimen.
Immunosuppression was reduced for the treatment of PTLD. Cyclosporine was stopped, and prednisolone (10 mg per day) was started. However, 12 months after liver transplantation, colon biopsy still showed monomorphic PTLD and a positive result for EBV in situ hybridization in succession. Pancytopenia progressed because of engraftment failure. Fourteen months after liver transplantation (June 2006), she received peripheral blood stem cell transplantation again from a 41-yr-old Taiwanese man who had 1 HLA Ag mismatch (CD34: $3.80 \times 10^6$/kg, CD3: $9.224 \times 10^7$/kg). The donor had positive results for EBV and CMV serologic tests. A combination of cyclophosphamide, ATG and TLI served as the conditioning regimen. After transplantation, immunosuppressive induction was achieved with cyclosporine. She suffered from diffuse alveolar hemorrhage, CMV antigenemia and hemorrhagic cystitis. There was no evidence of graft-versus-host disease (GVHD).

One month after the second HSCT, complete DNA chimerism was achieved, and the result of XX/XY FISH was 0.3%/99.7%. In addition, abdomen CT revealed that the size of intra-abdominal lymph nodes markedly decreased (Fig. 5). Colonoscopy revealed that multiple ulcers in the sigmoid colon disappeared (Fig. 6). Blind colon biopsy showed nonspecific inflammation. The level of EBV DNA was reduced to 68.65 copies per reaction.

Twenty months after HSCT, she is still alive under immunosuppression with cyclosporine, and there were no lymph node enlargement on abdomen CT scans.

**DISCUSSION**

To treat PTLD, various treatment strategies including chemotherapy, radiation therapy, antiviral therapy, anti-B-cell monoclonal antibody therapy and modalities for the restoration of EBV-specific cellular immunity, have been employed. Reduction of immunosuppression remains the first-line treatment, and many cases of polyclonal PTLD resolved completely in this manner. However, this was not the case for monochlonal PTLD. Thus, many other therapeutic trials have been attempted.

In this case, the patient underwent liver transplantation due to fulminant hepatitis and also underwent HSCT due to aplastic anemia. PTLD developed 11 months after liver transplantation. Immunosuppression reduction was ineffective in the treatment of PTLD. Recently several studies have supported the role of rituximab as a second-line therapy for PTLD (13-15). However, Rituximab was not administered to the patient because she had severe pancytopenia due to graft failure. A second HSCT can be effective in the treatment of PTLD. We hypothesized that HSCT of an unrelated donor, which contains cytotoxic T lymphocytes presensitized to EBV, might be an effective treatment method. The patient underwent a second HSCT from an unrelated donor, and the lesion of PTLD disappeared.

As mentioned earlier, deficiencies of EBV-specific T-cell-mediated immunity may cause PTLD. Therefore, treatment with EBV-specific cytotoxic T lymphocytes had been tried. Recent reports have documented the benefit of cellular therapy with EBV-specific cytotoxic T lymphocytes (16-20). Cytotoxic T lymphocytes from the blood of a donor are transfus-
ed into a recipient with PTLD. In this manner, remission of PTLD may serve as cellular therapy with cytotoxic T lymphocytes for PTLD.

In this case, we have shown that HSCT can treat PTLD and long-term survival is possible. The mechanism for this is unclear, but it is thought that HSCT serves as cellular therapy with cytotoxic T lymphocytes. Further investigations are needed to identify whether HSCT is an available cellular therapy for refractory PTLD.

REFERENCES

1. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-7.

2. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF, Deh JG. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-16.

3. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-53.

4. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, Lennette ET, Martinez OM, Krans SM, Berquist WE, So SK, Esquivel CO. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524-9.

5. Beveridge T, Knupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet 1984; 1: 788.

6. Trofe J, Beebe TM, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES. Posttransplant malignancy. Prog Transplant 2004; 14: 193-200.

7. Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381-94.

8. Lucas KG, Small TN, Heller G, Dupont B, O’reilly RJ. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 594-603.

9. Meij P, van Esser JW, Nieters HG, van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Lowenberg B, Cornelissen JJ, Gratama JW. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-7.

10. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-92.

11. American Society of Transplantation. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004; 4 (Suppl 10): 59-65.

12. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60-9.

13. Jain AB, Marcos A, Pokharna R, Fontes PA, Marsh W, Mohanka R, Fung JJ. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005; 80: 1692-8.

14. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot S, Guerreau Y, Stoppa AM, Bourjoud P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V. Humanized anti-CD20 monoclonal antibody (Rituximab) in post-transplant B lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-6.

15. Garcia VC, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, Barros V, Keitel B, Bittar AE, Ferreira dos Santos A, Rothmann S. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16: 202-6.

16. Papadopoulos EB, Laddany M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kerman NA, O’reilly RJ. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.

17. O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulouva L, Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195-216.

18. Haque T, Taylor C, Wilkie GM, Murad P, Anlot PL, Beath S, McKiernan P, Crawford DH. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein-Barr virus-specific cytotoxic T cells. Transplantation 2001; 72: 1399-402.

19. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.

20. Haque T, Wilkie GM, Taylor C, Anlot PL, Murad P, Beath S, Domboagoda D, Britton KM, Swordlow AJ, Crawford DH. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-42.